KALA - Kala Pharmaceuticals' Eysuvis Can Be A Rock Star In The Dry Eye Market

• Kala Pharmaceuticals’ Eysuvis, a corticosteroid-based drug, was approved for treating both signs and symptoms of dry eye disease last year and launched in Jan 2021.
• Eysuvis’ unique treatment target - dry eye flare - makes it a complementary therapy, rather than a direct competitor to other chronic dry eye drugs in a highly competitive market.
• The incredibly fast action time and excellent safety profile of Eysuvis make it very attractive for dry eye disease patients who also suffer from dry eye flares.
• Kala Pharmaceuticals is significantly undervalued if Eysuvis can somewhat successfully penetrate the dry eye disease market.
• I see 240+% upsides for Kala’s share price in 5 years.

For further details see: